Top 20 Life Science Startup Investors in Oceania in July 2025
A list of 20 angel investors and VC (Venture Capital) funds that invest in Life science startups based in Oceania. We rank investors based on the number of investments they made in Life science companies from Oceania. We update this investor list every month.Top 20 Life Science Startup Investors in Oceania in July 2025
Investor | Life Science Oceania investments |
---|---|
Main Sequence Ventures | 2 |
Churchill Asset Management | 1 |
The March Group | 1 |
Accelerating Commercialisation - AusIndustry | 1 |
Bioplatforms Australia | 1 |
Flintco, LLC | 1 |
Uniseed | 1 |
Alberici | 1 |
Possible Ventures | 1 |
OneVentures | 1 |
Alium Capital | 1 |
Tin Alley Ventures | 1 |
Catalio Capital Management | 1 |
AbbVie Biotech Ventures | 1 |
Skalata | 1 |
Riverlane Capital | 1 |
Benny Kleist | 1 |
Uniseed Ventures | 1 |
Medical Research Commercialisation Fund (MRCF) | 1 |
Breakthrough Victoria | 1 |
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Seed, Series A, Series B
- Australia, United States, Philippines
Portfolio highlights
- Levur — Levur produces oils inspired by nature, without the environmental impact. Our vision is a future where reliance on unsustainable plant and animal oils like Palm Oil is drastically reduced, mitigating environmental impacts. We are collaborating with large consumer goods manufacturers to make this a
- Arkeus — Arkeus is a leader in the fusion of optics and autonomy. Our wide area autonomous optical systems are deployed to conduct Search, Intelligence, Surveillance and Reconnaissance in a range of operating environments.
- QuintessenceLabs — Quantum cyberattacks can break current encryption in minutes! Get protected with QuintessenceLabs quantum key distribution, generation, and management.
Churchill is a leading capital provider for private equity-owned, middle market companies. We provide first lien, unitranche, second lien and mezzanine debt, in addition to equity co-investments, secondary solutions and private equity fund commitments.
Show more
Investment focus
- Health Care, Pet, Dental
- Debt Financing, Private Equity
- United States
Portfolio highlights
- Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
- Mosaic Dental Collective — Mosaic Dental Collective provides administrative and business operations support to dental practices. They are a multi-specialty group where doctors make decisions and are supported by an experienced professional management team.
- Heartland Veterinary Partners — Heartland Veterinary Partners purchases practices, providing operational support for payroll, HR, marketing, and more. Veterinarians can focus on patient care.
A venture capital fund platform committed to supporting and investing in entrepreneurs and companies developing and bringing exponential technologies to food, health and sustainability. March's investment strategy involves becoming recognized as the leading investor in critical and transformative technology solutions, and aims to achieve thisby investing into companies and funds that focus on developing core intellectual property around game-changing sustainable solutions that are aligned with globally relevant sustainability trends and benefits.
Show more
Investment focus
- SaaS, Energy, Retail
- Seed, Series A, Series C
- United States
Portfolio highlights
- Digestiva — We amplifye Protein.
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
A grant program offered by AusIndustry as part of the Australian Government’s National Innovation and Science Agenda
Show more
Investment focus
- Software, Mining, Hardware
- Grant, Pre-Seed
- Australia
Portfolio highlights
- Neuromersiv — Combining Virtual Reality, haptics and functional electrical stimulation, Neuromersiv is revolutionising brain rehabilitation therapy.Using a proprietary wearable device paired with a VR headset, Neuromersiv provides an engaging, immersive therapy experience in which patients perform gamified tasks ranging from picking up a toothbrush to climbingEverest! This unique approach increases dopamine activity in the brain, enhancing neuroplasticity, which is the brain’s ability to form new neural connections. Early trials of Neuromersiv technology have demonstrated 3x better outcomes as compared to traditional rehabilitation therapy resulting in faster independence and reduced care costs.
- Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
Bioplatforms Australia is a non-profit entity that supports life science research in genomic, proteomics, metabolomics, and bioinformatics.
Show more
Investment focus
- AgTech, Farming, Agriculture
- Pre-Seed
- Australia
Portfolio highlights
- Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
Flintco provides innovative construction solutions with an unrelenting focus on quality, safety, cost and schedule.
Show more
Investment focus
- Real Estate, Life Science, Property Management
- Seed
- Australia
Portfolio highlights
- LCG Capital Management — LCG Capital Management delivers expert real estate solutions, from property management in St. Louis, MO, to asset management & development.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more
Investment focus
- Biotechnology, Manufacturing, Health Care
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Diraq — Diraq uses spins in silicon quantum dots as qubits. Diraq's qubits are compatible with existing CMOS processes and can fit billions of qubits on a single chip. To transform our world, quantum computers need billions of qubits and Diraq has the IP, the team and the plan to get there.
- Celosia Therapeutics — The Celosia Therapeutics approach is the result of advances in gene therapies and a better understanding of the molecular pathways that contribute to neurodegenerative diseases.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Alberici is a diversified construction company recognized for superior quality and customer service. With operations throughout North America and clients around the world, they offer general contracting, construction management, and design-build solutions across a broad spectrum of industrial and commercial markets.
Show more
Investment focus
- Real Estate, Life Science, Property Management
- Seed
- Australia
Portfolio highlights
- LCG Capital Management — LCG Capital Management delivers expert real estate solutions, from property management in St. Louis, MO, to asset management & development.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more
Investment focus
- Software, Information Technology, Biotechnology
- Seed, Pre-Seed, Series A
- Germany, Australia, United States
Portfolio highlights
- Heidi Health — Heidi Health is modernizing primary care with AI-powered technologies to improve care's quality and accessibility. its creators and engineers is to completely eradicate missed and sluggish diagnoses worldwide. They are committed to bridging the gap between the level of care that patients desire and the level of care that doctors can delivergiven their budget constraints. To create a platform where patients can quickly and easily get the treatment they require and to give every clinician the resources they need to deliver care that is secure, efficient,
- ViridiCO2 — ViridiCO2 technology transforms Carbon Dioxide into a variety of high-value chemical intermediates.
- SWARM Biotactics — SWARM Biotactics develops Biobots that enter, sense, and report where nothing else can.
OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Debt Financing, Funding Round
- Australia, United States, Israel
Portfolio highlights
- Hometime — At Hometime, we provide Airbnb property management solutions for homeowners and rental management business owners that help them scale and earn more.
- StrongDM — Manage access to any server, database, or Kubernetes instance in minutes. Fully auditable, replayable, secure, and drag-and-drop easy.
- Employment Hero — Recruitment, HR, Payroll & Benefits in one place - designed for small & medium businesses to be efficient, compliant & cost-Effective. Book a demo today!
Alium Capital focuses on listed and unlisted technology investments to generate out-sized returns. The company invests in technology, innovation, and early-stage businesses, all the way through to publicly listed assets.
It specializes in the fields of finance, investing, innovation, and capital.Alium Capital was founded in 2016 andheadquartered in Sydney, New South Wales.
Show more
Investment focus
- Software, Financial Services, FinTech
- Series A, Series B, Seed
- Australia, United States, Singapore
Portfolio highlights
- Beforepay — Beforepay understands that traditional pay cycles are a form of financial stress. So we set out to find a better way, giving Australians the control and confidence that comes with managing your own money, on your terms.That’s why we created Pay On Demand™ - a service that allows you to access the money you have earned at work, when you choose todo so. After all, it is yours!The app also automatically predicts when your bills are due, shows you how much is OK for you to spend, and automatically creates budgets for you, effortlessly.
- Academy Xi — At Academy Xi, we help APAC's largest and most sophisticated organisations optimise performance with concise, actionable training solutions.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,293,506 freelance designers compete to create amazing designs for your business. Start Today!
Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.
Show more
Investment focus
- Medical, Health Care, Therapeutics
- Pre-Seed
- Australia
Portfolio highlights
- Cell Bauhaus — Cell Bauhaus uses mathematical and computer modeling to understand, predict, and modify living cell behavior, aiming to expedite sustainable solutions to humanity's pressing issues.
- Remagine Labs — Remagine Labs is revolutionizing healthcare with a bluetooth-connected, wearable electro-pharmaceutical that provide patient-centered care and consistent drug administration, giving healthcare customers peace of mind all over the world.
- Psychae Therapeutics — Psychae Therapeutics develop innovative pharmaceutical grade DMT-based medicines and therapies aiming to transform the lives of those facing some of the most prolific and insidious mental illnesses
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Israel, Switzerland
Portfolio highlights
- Visby Medical — Visby Medical is a medical diagnostics company with portable PCR testing technology for both clinical and mobile laboratory settings.
- Character Biosciences — Biopharmaceutical research and development company that's an affiliate of Clover Health
- Imbria Pharmaceuticals — Imbria is a clinical-stage, cardio-metabolic company developing innovative cellular energy enhancing therapies for the treatment of cardiovascular disorders
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, Italy
Portfolio highlights
- Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
- Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
- DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Giving Australian founders access to the education, capital and networks needed to build significant, sustainable, global businesses of the future.
Show more
Investment focus
- Software, Information Technology, Marketplace
- Pre-Seed, Seed
- Australia, United States, United Kingdom
Portfolio highlights
- TALY — TALY is a platform that is designed to find, manage and retain employees from both perfromance and personality for business development.
- Viewa — Viewa is an augmented reality(AR) content publishing platform that brings print media such as magazines to life in 3D.
- Enrola — Looking for online training courses? Discover the perfect course for you with our easy course advisor quiz. Get individual guidance and apply directly.
Long-term owner-operators of great Australian businesses.
Show more
Investment focus
- Life Science, Biotechnology, Venture Capital
- Series A
- Australia
Portfolio highlights
- Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
Benny Kleist is a Founder & COO of Eucalyptus.He attended The University of Queensland.
Show more
Investment focus
- Education, E-Learning, Life Science
- Pre-Seed, Series A
- Australia, New Zealand
Portfolio highlights
- Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
- NextWork — Building the best online learning experience to switch careers and upskill. Join the waitlist today, we are waiting for you!
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more
Investment focus
- Biotechnology, Manufacturing, Health Care
- Series A, Seed, Funding Round
- Australia, United States, United Kingdom
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Glyscend Therapeutics — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
The Breakthrough Victoria Fund is a $2 billion investment by the Victorian Government to drive investment in research and innovation.
Show more
Investment focus
- Manufacturing, Health Care, Software
- Funding Round, Series A, Seed
- Australia, United States, Philippines
Portfolio highlights
- EntroMat — EntroMat is a pioneering deep-tech startup transforming the metal powder industry through the advancement of high entropy material (HEM) powders.
- Umps Health — Umps offers a 24/7 personal alarm that helps you live independently with peace of mind. Easy to use, always connected.
- Quantum Brilliance — Quantum Brilliance builds room temperature quantum computers powered by synthetic diamond, enabling applications in everyday computing, including edge and massively parrellelized computing.
Investors by industry
Consumer
Proptech
Impact
Climate
Gaming
Biotech
FinTech
Marketplace
Community
Health Care
Hardware
Energy
Artificial intelligence
Google
EdTech
Sustainability
Venture Capital
Real Estate
Photography
Clean Energy
Music
Art
Education
Wellness
Franchise
B2B
Mobile
Local
Financial Services
Digital Media
Legal
Android
eSports
Enterprise Software
Sports
Manufacturing
Email
Medical
Social Network
Big Data
Social Media
Internet
Construction
Hospitality
Platforms
Biotechnology
Cannabis
Mobile Advertising
Travel
Fitness
Recruiting
Crowdfunding
Social
Medical Device
Automotive
Wine And Spirits
Payments
CleanTech
Mobile Apps
Transportation
InsurTech
Finance
Enterprise
Organic Food
Food and Beverage
LGBT
Web3
Infrastructure
Retail
Beauty
Publishing
Video Games
Life Science
Fashion
Oil and Gas
Theatre
Film
SaaS
Non Profit
Renewable Energy
Sporting Goods
Restaurants
Social Impact
Celebrity
Software
Cryptocurrency
Agriculture (agtech)
Machine Learning
Media (entertainment)
Facebook
Blockchain
Investors by country
Canada
Germany
United Kingdom
Ireland
South Korea
India
Australia
New Zealand
United States
Middle East
Brazil
LATAM
Qatar
Indonesia
Asia
Europe
Spain
South Africa
Singapore
Armenia
Saudi Arabia
Belarus
Chile
Sri Lanka
Belgium
China
Hong Kong
Finland
Ghana
Africa
Georgia
Ethiopia
Gibraltar
Faroe Islands
Oceania
Denmark
Egypt
Estonia
Costa Rica
Japan
Hungary
Greece
Barbados
Vietnam
Croatia
Belize
Bahrain
Czech Republic
Kuwait
Algeria
Ecuador
Bulgaria
Malta
Bermuda
France
Morocco
Poland
Senegal
Sierra Leone
Tunisia
Togo
Serbia
Turkey
San Marino
Thailand
Uzbekistan
Nicaragua
Taiwan
Sweden
Tanzania
Slovenia
El Salvador
Portugal
Mali
Tajikistan
Ukraine
Lithuania
Puerto Rico
Uganda
Venezuela
Uruguay
Zambia
Zimbabwe
Rwanda
Russian Federation
Dominican Republic
Peru
Nigeria
Iraq
Azerbaijan
Bahamas
Iceland
Namibia
Lebanon
United Arab Emirates
Jersey
Norway
Jamaica
Honduras
Myanmar
Mauritius
Bolivia
Isle of Man
Liberia
Mexico
Luxembourg
Malaysia
Albania
Pakistan
Liechtenstein
Philippines
Italy
Grenada
Jordan
Israel
Bangladesh
Argentina
Panama
Romania
Kenya
Kazakhstan
Cayman Islands
Cambodia
Latvia
Cyprus
Oman
Cameroon
Austria
Switzerland
Colombia
Guatemala
Seychelles
Marshall Islands
Investors in Oceania by industry
Restaurants
Crowdfunding
Retail
Social
Cryptocurrency
Finance
Real Estate
Food and Beverage
Video Games
Medical
Wine And Spirits
Organic Food
Medical Device
Wellness
Non Profit
Email
Enterprise
Internet
Social Network
Social Media
Art
Manufacturing
Music
Digital Media
Android
Mobile
Legal
Construction
Financial Services
Local
Software
eSports
Enterprise Software
Fitness
Hospitality
Automotive
CleanTech
Travel
Platforms
Sports
Biotechnology
Cannabis
Consumer
FinTech
Health Care
EdTech
Biotech
Climate
Sustainability
Impact
Energy
Proptech
Marketplace
SaaS
Community
Hardware
B2B
Fashion
Web3
Beauty
Big Data
Life Science
Blockchain
Publishing
Education
Sporting Goods
Oil and Gas
Renewable Energy
Clean Energy
Social Impact
Infrastructure
Mobile Apps
Photography
Transportation
Artificial intelligence
Venture Capital
Facebook
Agriculture (agtech)
Media (entertainment)
Machine Learning
InsurTech
Recruiting
Gaming
Payments